A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

May 31, 2009

Conditions

Cancer

Interventions

DRUG

APO010

APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.

Trial Locations (2)

Multidisciplinary Oncology Center, Cantonal University Hospital of Vaud, Lausanne

Oncology Institute of Southern Switzerland, Hospital of Bellinzona, Bellinzona